Francois Brisebois
Francois Brisbois is managing director and senior analyst at Oppenheimer & Co. Inc. covering biotechnology. Prior to joining Oppenheimer, he was a senior research analyst at Craig-Hallum Capital covering biotechnology and biopharmaceuticals. He previously worked at Laidlaw Capital Markets as a senior analyst covering biotechnology and specialty pharmaceuticals and started his Wall Street career at healthcare specialty firm Summer Street Research Partners. Brisebois holds a bachelor's degree in molecular biology from Colgate University and a Master of Science in pharmaceutical sciences from University of Montreal.
Recent Articles
Diagnostics Biotech Beats Revenue Estimates in Q3/23 10/11/2023
The Belgium-based company is well on its way to achieving, and possibly exceeding, full-year revenue guidance, noted an Oppenheimer report.
Biopharma Co. Adds CTO to Team 09/21/2023
This newest member brings with him extensive experience in protein development and manufacturing, noted an Oppenheimer report.
Recent Quotes
"DRRX already exceeded enrollment in its Phase 1b NASH trial."
—
Francois Brisebois, Craig-Hallum Capital
(3/4/20)
more >